Pablo E Visconti

US Patent:

7129057, Oct 31, 2006

Filed:

Nov 9, 2001

Appl. No.:

10/416477

Inventors:

John C. Herr - Charlottesville VA, US
Pablo E. Visconti - Amherst MA, US
Zhonglin Hao - Charlottesville VA, US
Gregory S. Kopf - Wynnewood PA, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA
The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

C12Q 1/48
C12N 9/12
C07K 1/00

US Classification:

435 15, 530350, 435194

Abstract:

The present invention relates to a family of testis specific kinases (the tssk family), nucleic acid sequences encoding those kinases and antibodies against the kinases. The invention is further directed to the use of thise kinases as targets for isolating specific inhibitors or anagonists of tssk kinase activity. Such inhibitors are anticipated to have use as contraceptive agents.

US Patent:

20020064849, May 30, 2002

Filed:

Sep 5, 2001

Appl. No.:

09/947124

Inventors:

John Herr - Charlottesville VA, US
Pablo Visconti - Charlottesville VA, US
Arabinda Mandal - Charlottesville VA, US
Vrinda Khole - Worli, IN

International Classification:

C12Q001/42
C07H021/04
A61K038/47
C12N009/16
C07K016/40
C12P021/02
C12N005/06

US Classification:

435/190000, 435/069100, 435/325000, 530/388260, 435/021000, 536/023200, 424/094610

Abstract:

The present invention relates to a newly identified human soluble adenylyl cyclase and nucleic acid sequences encoding the adenylyl cyclase. The invention further relates to methods of using the adenylyl cyclase polypeptides and polynucleotides as a targets for identifying agonists and antagonists that are selective for human soluble adenylyl cyclase. Inhibitors of human soluble adenylyl cyclase can be used as contraceptive agents.

US Patent:

20030211563, Nov 13, 2003

Filed:

May 9, 2003

Appl. No.:

10/438339

Inventors:

John Herr - Charlottesville VA, US
Pablo Visconti - Amherst MA, US
Zhonglin Hao - Charlottesville VA, US

International Classification:

C12Q001/48
C07H021/04
C12N009/12
C12P021/02
C12N005/06

US Classification:

435/015000, 435/069100, 435/194000, 435/320100, 435/325000, 536/023200

Abstract:

The present invention relates to a family of testis specific kinases (the tssk family), nucleic acid sequences encoding those kinases and antibodies against the kinases. The invention is further directed to the use of those kinases as targets for isolating specific inhibitors or antagonists of tssk kinase activity. Such inhibitors are anticipated to have use as contraceptive agents.

US Patent:

20050032146, Feb 10, 2005

Filed:

Jan 8, 2004

Appl. No.:

10/754829

Inventors:

John Herr - Charlottesville VA, US
Pablo Visconti - Amherst MA, US
Andrea Wagenfeld - Berlin, DE
Michael Coppola - Charlottesville VA, US
Zhonglin Hao - Charlottesville VA, US
Soumya Vemuganti - Charlottesville VA, US

International Classification:

C12Q001/48

US Classification:

435015000

Abstract:

The present invention relates to a family of testis specific kinases (the tssk family), nucleic acid sequences encoding those kinases and antibodies against the kinases. The invention is further directed to the use of the tssk 4 kinase and other members of the tssk kinase family as targets for isolating specific inhibitors or antagonists of tssk kinase activity. Such inhibitors are anticipated to have use as contraceptive agents.

US Patent:

20080175827, Jul 24, 2008

Filed:

Nov 19, 2007

Appl. No.:

11/942406

Inventors:

Rafael A. Fissore - Amherst MA, US
Pablo Visconti - Amherst MA, US
Manabu Kurokawa - Durham NC, US
Sook-Young Yoon - Amherst MA, US
Daniel R. Grow - Long Meadow MA, US
Teru J. Jellerette - Shutesbury MA, US
Jose Bernardo Cibelli - East Lansing MI, US
Pablo Juan Ross - Bath MI, US

Assignee:

Michigan State University - East Lansing MI
University of Massachussetts - Boston MA
Baystate Health, Inc. - Springfield MA

International Classification:

A61K 48/00
C12N 5/00
C12N 15/00
C12Q 1/68
A01N 1/02
C12Q 1/42

US Classification:

424 9321, 435377, 435455, 435 2, 435 21, 435 6

Abstract:

The invention relates to the use of phospholipase C zeta in inducing or promoting the activation of oocytes, preferably human oocytes, nuclear transfer embryos, parthenogenic embryos, cross species embryos and during in vitro fertilization.The invention further relates to methods of detecting levels of expression of phospholipase c zeta in sperm as a means of detecting male infertility.The invention also relates to the use of phospholipase C zeta to treat male infertility. Still further the invention relates to the recombinant cells that are engineered to express phospholipase C zeta, preferably under inducible conditions.Also, the invention relates to antibodies specific to phospholipase C zeta, preferably human phospholipase C zeta.